Drugs / MPB-1734
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04643418 | Mar 2022 → Mar 2025 overdue | cancer | MegaPro Biomedical Co. Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MPB-1734 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04643418 ↗ |
| Route | Intravenous | “intravenous, once per 3 weeks, starting at 10 mg/m˄2” NCT04643418 ↗ |